Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
22.05 USD | -0.45% | +6.56% | -1.82% |
Apr. 29 | North American Morning Briefing : Investors Brace -2- | DJ |
Mar. 25 | Cassava Sciences Announces Completion of Interim Safety Review for Alzheimer's Drug Candidate Simufilam | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-1.60% | 958M | |
-3.46% | 102B | |
+1.41% | 96.09B | |
+2.13% | 22.28B | |
-15.84% | 21.4B | |
-9.35% | 18.14B | |
-39.98% | 17.02B | |
-14.65% | 16.09B | |
+4.39% | 13.83B | |
+31.35% | 11.97B |
- Stock Market
- Equities
- SAVA Stock
- News Cassava Sciences, Inc.
- Univest Securities Starts Cassava Sciences at Sell With $8 Price Target, Says Phase 3 Trials Unlikely to Lead to Commercialization, Expects Further Stock Dilution